10X Genomics (ticker: $TXG) reported revenue of approximately $151.7 million for the third quarter ending September 30, 2024, reflecting a 1% decrease compared to the same period last year. The company's earnings report led to a significant drop in its stock price, which fell by 26% in pre-market trading following the announcement. Hedgeye, a financial research firm, has been vocal about its bearish stance on $TXG, with analyst Tobin noted for his short call on the stock since March 2022. At its peak, $TXG traded at $202 in 2021 but has since faced challenges, including the recent disappointing earnings results that have raised concerns about its future performance.